http://www.pnas.org/...809232115.short
Immunization against a genetically engineered tumor-specific antigen, ovalbumin, when adjuvanted with Diprovocim, inhibited growth of B16 melanoma and prolonged survival in the presence of immune checkpoint blockade by anti–PD-L1; 100% of mice responded to treatment. Our data suggest Diprovocim boosts the success of anti–PD-L1 treatment by increasing the number and activation of tumor-specific CTLs capable of responding to this checkpoint inhibitor.
This sounds like good news for Melanoma, these are existing compounds
I found this portion interesting:
We report the immunological effects of the synthetic chemical adjuvant Diprovocim, which targets the innate immune receptor TLR1/TLR2 in mice and humans.
Some research indicates that TLR2 is upregulated in senescene process, so perhaps combing senolytics with Diprovocim would increase effectiveness.